Additionally, the 36-month beta value for LCTX is 1.17. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LCTX is 218.96M and currently, short sellers hold a 8.38% ratio of that float. The average trading volume of LCTX on December 18, 2024 was 1.64M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
LCTX) stock’s latest price update
Lineage Cell Therapeutics Inc (AMEX: LCTX)’s stock price has gone rise by 12.89 in comparison to its previous close of 0.50, however, the company has experienced a -8.43% decrease in its stock price over the last five trading days. zacks.com reported 2024-12-17 that The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
LCTX’s Market Performance
Lineage Cell Therapeutics Inc (LCTX) has seen a -8.43% fall in stock performance for the week, with a -36.21% decline in the past month and a -38.36% plunge in the past quarter. The volatility ratio for the week is 10.69%, and the volatility levels for the past 30 days are at 11.14% for LCTX. The simple moving average for the last 20 days is -0.56% for LCTX’s stock, with a simple moving average of -41.95% for the last 200 days.
Analysts’ Opinion of LCTX
Many brokerage firms have already submitted their reports for LCTX stocks, with Craig Hallum repeating the rating for LCTX by listing it as a “Buy.” The predicted price for LCTX in the upcoming period, according to Craig Hallum is $4 based on the research report published on August 20, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see LCTX reach a price target of $5. The rating they have provided for LCTX stocks is “Outperform” according to the report published on November 02nd, 2022.
B. Riley Securities gave a rating of “Buy” to LCTX, setting the target price at $4 in the report published on June 14th of the previous year.
LCTX Trading at -25.27% from the 50-Day Moving Average
After a stumble in the market that brought LCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.16% of loss for the given period.
Volatility was left at 11.14%, however, over the last 30 days, the volatility rate increased by 10.69%, as shares sank -38.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.45% lower at present.
During the last 5 trading sessions, LCTX fell by -9.89%, which changed the moving average for the period of 200-days by -48.89% in comparison to the 20-day moving average, which settled at $0.5637. In addition, Lineage Cell Therapeutics Inc saw -48.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LCTX starting from Howe Jill Ann, who purchase 15,000 shares at the price of $0.59 back on Nov 26 ’24. After this action, Howe Jill Ann now owns 25,500 shares of Lineage Cell Therapeutics Inc, valued at $8,850 using the latest closing price.
Samuel George A. III, the General Counsel of Lineage Cell Therapeutics Inc, purchase 15,000 shares at $0.60 during a trade that took place back on Nov 26 ’24, which means that Samuel George A. III is holding 22,184 shares at $9,000 based on the most recent closing price.
Stock Fundamentals for LCTX
Current profitability levels for the company are sitting at:
- -2.61 for the present operating margin
- 0.91 for the gross margin
The net margin for Lineage Cell Therapeutics Inc stands at -2.31. The total capital return value is set at -0.27. Equity return is now at value -29.95, with -19.84 for asset returns.
Currently, EBITDA for the company is -24.04 million with net debt to EBITDA at 1.22. When we switch over and look at the enterprise to sales, we see a ratio of 11.3. The receivables turnover for the company is 21.53for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.48.
Conclusion
In conclusion, Lineage Cell Therapeutics Inc (LCTX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
